Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Pancreatic Neoplasms 5Prostatic Neoplasms 4Lung Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Multiple Myeloma 3Melanoma 3Carcinoma, Intraductal, Noninfiltrating 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Thrombocytosis 2Stomach Neoplasms 2Myeloproliferative Disorders 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma, Kaposi 1Sarcoma 1Rhabdomyosarcoma 1Resectable Pancreatic Carcinoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1

Interventions

navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Plasmacytoma × Specimen Handling × Clear all
NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Terminated
35 enrolled 10 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡